Key Highlights
- Third-quarter Revenue rose 129% to USD 244,034.
- Specimen count rose 169% to 752 from 280.
- Net loss narrowed 20% to USD 2.2 million.
- Cash was USD 5.6 million at September 30.
iSpecimen Inc. (NASDAQ:ISPC) reported third-quarter 2026 revenue of USD 244,034 versus USD 106,592, an increase of 129%. Specimen count rose about 169%, to 752 from 280, which the company tied to higher customer orders and procurement. The average selling price per specimen fell about 15%, to roughly USD 325 from USD 381.
Total operating expenses fell 17% to USD 2,441,243 from USD 2,936,814, and the loss from operations narrowed 22% to USD 2,197,209. The net loss was USD 2,211,994 versus USD 2,780,648, or USD 1.03 per share versus USD 19.05. The Earnings calendar carried no estimates for the quarter.
Revenue growth in the quarter sits against a nine-month comparison that is still negative, and the company attributes the quarterly increase to higher customer orders and procurement, with a lower average price per specimen.
The filing also lists cash and cash equivalents and total Assets alongside these results, which the company reports for the three and nine months ended September 30, 2026.
Expense Detail
Cost of revenue fell 55% to USD 91,156, helped by an 83% drop in average cost per specimen. Technology expense fell 48% to USD 286,543, mainly on lower amortization of internally developed software, while about USD 700,000 of technology spending was capitalized as software after a platform milestone was completed.
Sales and Marketing rose 21% to USD 1,379,947, driven by Advertising and promotion. General and administrative expense fell 37% to USD 547,984, and fulfillment fell 30% to USD 106,977. Interest expense was USD 27,500.
Sales and marketing for nine months rose sharply on advertising and promotion costs, while professional fees fell and compensation costs declined by about USD 123,000 in general and administrative expense. Loss from operations improved 3% for the nine months, and the net loss rose 7%.
Nine-Month Results and Cash
For nine months, revenue was USD 551,983 versus USD 1,877,237, a 71% decrease. Operating expenses fell 19% to USD 6,650,580, the loss from operations was USD 6,098,597 versus USD 6,290,037, and the net loss was USD 5,850,026 versus USD 5,486,287, with a loss per share of USD 4.49 versus USD 61.54.
Cash and cash equivalents fell 19% to USD 5,556,914 from USD 6,880,835, and total assets were USD 9,700,831 versus USD 9,531,410.
The filing notes that revenue declined about 71% for nine months, with sales and marketing costs up primarily on advertising and promotion. Other income, net, fell 74% in the quarter to USD 12,442. Supply development expense rose 28% to USD 28,636, and interest expense was USD 27,500 versus USD 2 a year earlier.
Business Profile and Items to Follow
The company has built a "proprietary online marketplace platform" connecting medical researchers with hospitals, laboratories and other holders of biospecimens such as biofluids, tissues and living cells. It was incorporated in Delaware in 2009.
Items to follow include whether higher specimen volumes persist, pricing per specimen, advertising and promotion spend and the pace of cash use against the USD 5.6 million balance.
The filing also reports cash and cash equivalents down 19% and total assets up 2% since year-end.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...